Less Ads, More Data, More Tools Register for FREE

Pin to quick picksXaar Regulatory News (XAR)

Share Price Information for Xaar (XAR)

Share Price is delayed by 15 minutes
Get Live Data
145.00    3.00 (2.11%)
Bid:
140.50
Ask:
144.50
Spread: 4.00 (2.847%)
Market Cap: £113.79m
XAR Live PriceLast checked at - London Stock Exchange

Intraday Xaar Share Chart

Trading update & revised date for interim results

3 Sep 2019 07:00

RNS Number : 9703K
Xaar PLC
03 September 2019
 

Xaar plc

 

Trading update and revised date for interim results 

 

Xaar plc ("Xaar" or the "Group") provides an update on trading and notifies a revised date for presentation of interim results and an update on its strategic review of the Thin Film business.

Revenue in the first half year to 30 June 2019 was £22.5 million, as previously announced, including the impact of a £4.3 million revenue reversal relating to Xaar 1201 Thin Film printhead inventory being returned to the business. As part of the interim results process, a review of the Group's holding of Xaar 1201 printhead inventory and near term prospects for sale has taken place which has resulted in a reassessment of realisable value. We now consider it prudent to make a provision of £5.7 million which will be reflected in our first half results.

Trading for the remainder of the year is expected to be weaker than previously anticipated. This is principally due to lower sales volumes of Xaar 1201 and Xaar 2001 printheads as a result of slower than expected new printer installs by OEMs and credit and sales channel issues on Xaar 1201. As a result, the Board now expects sales in the second half of the year to be similar to those in the first half.

The Group had net cash balances at 30 June 2019 of £21.6 million.

Management continues to focus on its strategic negotiations and expects that some additional time could enable the Board to provide a more meaningful update on progress, including any effect this may have on our interim results statement. Hence we are deferring the announcement of our interim results to 26 September from the previously announced date of 10 September.

 

 

Enquiries:

Xaar plc

+44 (0)1223 423 663 

Doug Edwards, Chief Executive Officer

Shomit Kenkare, Chief Financial Officer

 

 

Tulchan Communications

+44 (0)20 7353 4200

James Macey White

David Ison

 

About XaarXaar is a world leader in the development of digital inkjet technology. Our technology drives the conversion of analogue printing and manufacturing methods to digital inkjet which is more efficient, more economical and more productive than the traditional methods which have been in use for years. We design and manufacture printheads as well as systems for product decoration and industrial 3D Printing which use our inkjet technology. We are the only truly independent inkjet technology company with over 25 years of know how. We offer unrivalled inkjet expertise including technology and printhead design and development, and manufacture highly customised product decoration systems and industrial 3D Printing for volume manufacturing. Our unique technologies and products are the leading enabler for innovation and for driving supply chain efficiencies for many industries. Information about Xaar is at www.xaar.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
TSTUGUWGBUPBGMP
Date   Source Headline
2nd Jun 202612:58 pmRNSTotal Voting Rights
28th May 20269:18 amRNSResult of AGM
6th May 20267:00 amRNSDirector/PDMR Shareholding
5th May 202611:36 amRNSHolding(s) in Company
30th Apr 20264:44 pmRNSHolding(s) in Company
16th Apr 20269:00 amRNSPublication of Annual Report and Notice of AGM
1st Apr 20263:43 pmRNSHolding(s) in Company
24th Mar 20267:05 amRNSFinal Results
23rd Mar 20263:33 pmRNS-RInvestor Presentation via Investor Meet Company
2nd Mar 20262:44 pmRNSTotal Voting Rights
14th Jan 20267:00 amRNSTrading Statement
5th Jan 202612:28 pmRNSTotal Voting Rights
5th Dec 20251:15 pmRNSHolding(s) in Company
1st Dec 202512:15 pmRNSTotal Voting Rights
24th Nov 202511:00 amRNSDirector/PDMR Shareholding
3rd Nov 20252:00 pmRNSTotal Voting Rights
21st Oct 20254:15 pmRNSDirector/PDMR Shareholding
13th Oct 20253:20 pmRNSHolding(s) in Company
2nd Oct 202511:10 amRNSDirector/PDMR Shareholding
2nd Oct 20258:50 amRNSDirector/PDMR Shareholding
1st Oct 20255:00 pmRNSDirector/PDMR Shareholding
1st Oct 20253:30 pmRNSTotal Voting Rights
1st Oct 202512:04 pmRNSTRADING UPDATE and NOTICE OF RESULTS
1st Sep 20254:30 pmRNSTotal Voting Rights
12th Aug 20257:00 amRNS2025 INTERIM RESULTS
5th Aug 20257:00 amRNSBoard changes
1st Aug 20253:45 pmRNSTotal Voting Rights
14th Jul 202510:00 amRNSNotice of Interim Results
7th Jul 20253:30 pmRNSBlock listing Interim Review
2nd Jul 20253:30 pmRNSTotal Voting Rights
30th Jun 20252:00 pmRNSDirector/PDMR Shareholding
3rd Jun 202510:00 amRNSTotal Voting Rights
28th May 20253:30 pmRNSResult of AGM
21st May 20251:00 pmRNSHolding(s) in Company
7th May 20253:30 pmRNSNotification of Transactions of Directors & PDMRs
2nd May 202510:30 amRNSTotal Voting Rights
15th Apr 20251:15 pmRNS2024 Annual Report and Notice of AGM
11th Apr 202512:00 pmRNSHolding(s) in Company
1st Apr 20254:15 pmRNSHolding(s) in Company
1st Apr 20253:30 pmRNSTotal Voting Rights
31st Mar 20253:45 pmRNSNotification of Transactions of Directors & PDMRs
31st Mar 20251:10 pmRNSHolding(s) in Company
28th Mar 202511:30 amRNSHolding(s) in Company
27th Mar 202511:00 amRNSHolding(s) in Company
25th Mar 20255:00 pmRNSNotification of Transactions of Directors & PDMRs
25th Mar 20257:00 amRNSFinal Results
5th Mar 202511:30 amRNSTotal Voting Rights
19th Feb 202510:30 amRNSHolding(s) in Company
10th Feb 202511:00 amRNSHolding(s) in Company
5th Feb 20254:00 pmRNSHolding(s) in Company

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.